Nitrate ( DrugBank: Nitrate )


4 diseases
告示番号疾患名(ページ内リンク)臨床試験数
58肥大型心筋症2
67多発性嚢胞腎1
113筋ジストロフィー3
299嚢胞性線維症4

58. 肥大型心筋症


臨床試験数 : 126 薬物数 : 135 - (DrugBank : 42) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 162
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03832660
(ClinicalTrials.gov)
May 3, 20191/2/2019Sacubitril/Valsartan vs Lifestyle in Hypertrophic CardiomyopathyClinical and Genetic Determinants of Disease Progression and Response to Sacubitril/Valsartan vs Lifestyle (Physical Activity and Dietary Nitrate) in Patients With Hypertrophic CardiomyopathyHypertrophic CardiomyopathyBehavioral: Lifestyle;Drug: Sacubitril/ValsartanNewcastle UniversityAzienda Ospedaliero-Universitaria Careggi;University Hospital Regensburg;Institute for Cardiovascular Diseases of Vojvodina;University of BelgradeCompleted18 Years70 YearsAll168Phase 2Germany;Italy;Serbia;United Kingdom
2NCT03251287
(ClinicalTrials.gov)
November 201711/8/2017Nitrite in Hypertrophic Cardiomyopathy (HCM) StudyMechanistic Study of the Effect of Inorganic Sodium Nitrate on Cardiac and Skeletal Muscle Metabolic Efficiency in Patients With Hypertrophic CardiomyopathyCardiomyopathy, HypertrophicDrug: Sodium Nitrate;Drug: Placebo;Diagnostic Test: Phosphorous Magnetic Resonance Spectroscopy;Diagnostic Test: Exercise Stress Transthoracic EchocardiogramUniversity of East AngliaNorfolk and Norwich University Hospitals NHS Foundation Trust;British Medical Research CouncilRecruiting18 Years80 YearsAll18Phase 1United Kingdom

67. 多発性嚢胞腎


臨床試験数 : 221 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05401409
(ClinicalTrials.gov)
May 5, 202227/5/2022Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney DiseaseDouble-Blind, Randomised Placebo-Controlled Study to Determine the Effect of Beetroot Juice on Reducing Blood Pressure in Hypertensive Adults With Autosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic Kidney;Hypertension;Endothelial DysfunctionDietary Supplement: Beetroot juice;Dietary Supplement: Nitrate-depleted beetroot juiceWestern Sydney Local Health DistrictWestmead Institute for Medical ResearchRecruiting18 Years70 YearsAll60N/AAustralia

113. 筋ジストロフィー


臨床試験数 : 646 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02434627
(ClinicalTrials.gov)
June 201528/4/2015Sodium Nitrate for Muscular DystrophySodium Nitrate for Muscular DystrophyBecker Muscular DystrophyDrug: Sodium NitrateCedars-Sinai Medical CenterNULLCompleted15 Years45 YearsMale5Phase 1United States
2NCT02847975
(ClinicalTrials.gov)
October 201330/4/2014Sodium Nitrate to Improve Blood FlowSodium Nitrate to Improve Blood FlowBecker Muscular DystrophyDietary Supplement: Sodium nitrateCedars-Sinai Medical CenterNULLCompleted15 Years55 YearsMale11Phase 1United States
3NCT02147639
(ClinicalTrials.gov)
October 201325/3/2014Effects of Sodium Nitrate on Blood Flow in Becker Muscular DystrophyBecker Muscular DystrophyDietary Supplement: Sodium Nitrate;Dietary Supplement: Sodium Nitrate - double dose;Dietary Supplement: Placebo;Procedure: Increased exercise intensityCedars-Sinai Medical CenterNULLCompleted15 Years45 YearsMale19Phase 2/Phase 3United States

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04294043
(ClinicalTrials.gov)
June 17, 20211/3/2020IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)A Phase 1b, Multi-center Study of Intravenous (IV) Gallium Nitrate in Patients With Cystic Fibrosis (CF) Who Are Colonized With Nontuberculous Mycobacteria (NTM) (The ABATE Study)Nontuberculous Mycobacterium InfectionDrug: Gallium nitrateChris GossCystic Fibrosis FoundationRecruiting18 YearsN/AAll40Phase 1United States
2NCT02354859
(ClinicalTrials.gov)
March 201630/7/2014A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)Cystic FibrosisDrug: Gallium nitrate;Drug: Normal SalineUniversity of WashingtonCystic Fibrosis FoundationCompleted18 YearsN/AAll119Phase 2United States
3NCT02310789
(ClinicalTrials.gov)
July 31, 20153/9/2014(Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil?(Study: Vertex IIS) A Study To Access the Effects of Ivacaftor on Wild Type CFTR-Open Probability (PO) In The Sweat Gland Secretory CoilCystic FibrosisDrug: Ivacaftor;Drug: ß-Adrenergic cocktail;Drug: Pilocarpine Nitrate 5%;Device: Macroduct sweat stimulatorRichard Barry MossNULLCompleted18 YearsN/AAll8N/AUnited States
4NCT01093521
(ClinicalTrials.gov)
April 201024/3/2010A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis PatientsA Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis PatientsCystic FibrosisDrug: 100 mg/m2 dose;Drug: 200 mg/m2 doseUniversity of WashingtonCystic Fibrosis FoundationCompleted18 Years55 YearsAll20Phase 1United States